Małgorzata Gałecka1, Katarzyna Bliźniewska-Kowalska2, Agata Orzechowska2, Janusz Szemraj3, Michael Maes4, Michael Berk5,6, Kuan-Pin Su7, Piotr Gałecki2. 1. Department of Psychotherapy, Medical University of Lodz, 91-229 Lodz, Poland. 2. Department of Adult Psychiatry, Medical University of Lodz, 91-229 Lodz, Poland. 3. Department of Medical Biochemistry, Medical University of Lodz, 92-215 Lodz, Poland. 4. Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand. 5. IMPACT-The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Deakin University, Geelong, VIC 3220, Australia. 6. Orygen, The National Centre of Excellence in Youth Mental Health, The Department of Psychiatry and The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC 3010, Australia. 7. An-Nan Hospital, China Medical University, Tainan 709, Taiwan.
Abstract
BACKGROUND: The authors of this research study intended to verify whether there are any changes in gene expression in depressed patients without coexisting inflammatory diseases for selected immune-inflammatory factors that are particularly important in autoimmune disease pathogenesis (IL-17, IL-21, IL-23, IL-35, Foxp3). METHODS: The study was carried out on a group of 190 patients with depression and 100 healthy volunteers. The severity of depressive symptoms was assessed using the Hamilton Depression Scale. RT-PCR was used to evaluate mRNA expression and ELISA was used to measure protein expression of these genes. RESULTS: The level of gene expression for IL-17, IL-21, IL-23, and IL-35 was substantially higher in the group of patients with depression compared to the control group. The mean mRNA expression of Foxp3 was considerably reduced in patients suffering from depressive disorders. There was a statistically significant correlation between the number of hospitalizations and the expression of specific inflammatory factors. CONCLUSIONS: Expression of specific inflammatory genes may be a factor in the etiopathogenesis of depressive disorders. The duration of the disease seems to be more important for the expression of the genes in question than the severity of depression. These cytokines may affect the metabolism of neurotransmitters and neuroendocrine functions in the brain as well as be a marker and a new potential therapeutic target for recurrent depressive disorders.
BACKGROUND: The authors of this research study intended to verify whether there are any changes in gene expression in depressedpatients without coexisting inflammatory diseases for selected immune-inflammatory factors that are particularly important in autoimmune disease pathogenesis (IL-17, IL-21, IL-23, IL-35, Foxp3). METHODS: The study was carried out on a group of 190 patients with depression and 100 healthy volunteers. The severity of depressive symptoms was assessed using the Hamilton Depression Scale. RT-PCR was used to evaluate mRNA expression and ELISA was used to measure protein expression of these genes. RESULTS: The level of gene expression for IL-17, IL-21, IL-23, and IL-35 was substantially higher in the group of patients with depression compared to the control group. The mean mRNA expression of Foxp3 was considerably reduced in patients suffering from depressive disorders. There was a statistically significant correlation between the number of hospitalizations and the expression of specific inflammatory factors. CONCLUSIONS: Expression of specific inflammatory genes may be a factor in the etiopathogenesis of depressive disorders. The duration of the disease seems to be more important for the expression of the genes in question than the severity of depression. These cytokines may affect the metabolism of neurotransmitters and neuroendocrine functions in the brain as well as be a marker and a new potential therapeutic target for recurrent depressive disorders.
Authors: Claire L Langrish; Brent S McKenzie; Nicholas J Wilson; Rene de Waal Malefyt; Robert A Kastelein; Daniel J Cua Journal: Immunol Rev Date: 2004-12 Impact factor: 12.988
Authors: Courtney R Rivet-Noor; Andrea R Merchak; Sihan Li; Rebecca M Beiter; Sangwoo Lee; Jalon Aaron Thomas; Anthony Fernández-Castañeda; Jung-Bum Shin; Alban Gaultier Journal: Sci Rep Date: 2022-05-21 Impact factor: 4.996
Authors: Małgorzata Gałecka; Janusz Szemraj; Kuan-Pin Su; Angelos Halaris; Michael Maes; Aleksandra Skiba; Piotr Gałecki; Katarzyna Bliźniewska-Kowalska Journal: J Clin Med Date: 2022-04-06 Impact factor: 4.241
Authors: Katarzyna Wachowska; Piotr Gałecki; Janusz Szemraj; Janusz Śmigielski; Agata Orzechowska Journal: J Clin Med Date: 2022-04-01 Impact factor: 4.241